Immunovant, Inc. (IMVT)

Immunovant Income Statement

Financials in millions USD. Fiscal year is April - March.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
Selling, General & Admin	71.88	57.28	48.02	54.23	39.51	15.85
Research & Development	333.32	212.93	160.26	101.81	68.6	47.93
Operating Expenses	405.21	270.21	208.28	156.03	108.12	63.78
Operating Income	-405.21	-270.21	-208.28	-156.03	-108.12	-63.78
Interest Expense	-	-	-	-	-	-0.63
Interest & Investment Income	26.22	24.95	7.58	-	-	-
Other Non Operating Income (Expenses)	-3.19	-1.01	-0.25	-0.78	0.33	0.41
EBT Excluding Unusual Items	-382.17	-246.27	-200.95	-156.81	-107.79	-63.99
Merger & Restructuring Charges	-	-	-	-	-	-2.3
Pretax Income	-382.17	-258.77	-210.95	-156.81	-107.79	-66.29
Income Tax Expense	0.54	0.57	0.01	-0.08	-0.36	0.1
Net Income	-382.71	-259.34	-210.96	-156.73	-107.43	-66.39
Net Income to Common	-382.71	-259.34	-210.96	-156.73	-107.43	-66.39
Shares Outstanding (Basic)	146	138	123	110	88	43
Shares Outstanding (Diluted)	146	138	123	110	88	43
Shares Change (YoY)	9.00%	12.21%	12.21%	24.98%	103.14%	94.85%
EPS (Basic)	-2.62	-1.88	-1.71	-1.43	-1.22	-1.54
EPS (Diluted)	-2.62	-1.88	-1.71	-1.43	-1.22	-1.54
Free Cash Flow	-325.64	-214.59	-188.39	-106.37	-83.54	-53.39
Free Cash Flow Per Share	-2.23	-1.55	-1.53	-0.97	-0.95	-1.24
EBITDA	-404.87	-269.98	-208.08	-155.91	-108.05	-63.76
D&A For EBITDA	0.33	0.23	0.19	0.13	0.07	0.02
EBIT	-405.21	-270.21	-208.28	-156.03	-108.12	-63.78

Updated Feb 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q